Welcome to the new morningstar.co.uk! Learn more about the changes and how our new features help your investing success.

Redx Pharma Nominates First Development Compound To Treat Fibrosis

LONDON (Alliance News) - Redx Pharma PLC said Wednesday that it nominated the first development ...

Alliance News 14 November, 2018 | 11:17AM
Email Form

LONDON (Alliance News) - Redx Pharma PLC said Wednesday that it nominated the first development compound to treat fibrosis.

The new candidate, RXC006, is an oral porcupine inhibitor that will be developed as a first-in-class treatment for idiopathic pulmonary fibrosis, a severe and life-threatening chronic lung condition with very poor prognosis and limited treatment options, the drug development company explained.

The company will present pre-clinical data, which showed that the compound is "very potent and highly effective", at the Anti-Fibrotic Drug Development summit, in the US, at the end of November.

Furthermore, the first in-man study for the product have been earmarked for 2020.

Redx shares were trading down 2.1% at 6.95 pence each.

By Elena Cherubini; elenacherubini@alliancenews.com

Copyright 2018 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Redx Pharma PLC 7.00 GBX 0.00 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites